Company’s 36-month beta value is 0.68.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QNCX is 32.66M, and currently, short sellers hold a 7.77% ratio of that floaft. The average trading volume of QNCX on March 14, 2025 was 125.86K shares.
QNCX) stock’s latest price update
Quince Therapeutics Inc (NASDAQ: QNCX)’s stock price has plunge by -5.37relation to previous closing price of 1.49. Nevertheless, the company has seen a -6.00% plunge in its stock price over the last five trading sessions. businesswire.com reported 2025-02-07 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $QNCX #biotech–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced that it will host an investor webinar today, Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time, featuring key opinion leader (KOL) Dr. Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia.
QNCX’s Market Performance
QNCX’s stock has fallen by -6.00% in the past week, with a monthly rise of 0.71% and a quarterly drop of -30.88%. The volatility ratio for the week is 7.81% while the volatility levels for the last 30 days are 6.64% for Quince Therapeutics Inc The simple moving average for the past 20 days is -1.61% for QNCX’s stock, with a 19.74% simple moving average for the past 200 days.
QNCX Trading at -10.64% from the 50-Day Moving Average
After a stumble in the market that brought QNCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.45% of loss for the given period.
Volatility was left at 6.64%, however, over the last 30 days, the volatility rate increased by 7.81%, as shares surge +0.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.94% lower at present.
During the last 5 trading sessions, QNCX fell by -6.00%, which changed the moving average for the period of 200-days by +62.07% in comparison to the 20-day moving average, which settled at $1.4330. In addition, Quince Therapeutics Inc saw -24.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNCX starting from Thye Dirk, who purchase 77,000 shares at the price of $0.70 back on Aug 30 ’24. After this action, Thye Dirk now owns 843,941 shares of Quince Therapeutics Inc, valued at $53,900 using the latest closing price.
Thye Dirk, the CEO AND CHIEF MEDICAL OFFICER of Quince Therapeutics Inc, purchase 77,500 shares at $0.69 during a trade that took place back on Aug 29 ’24, which means that Thye Dirk is holding 766,941 shares at $53,475 based on the most recent closing price.
Stock Fundamentals for QNCX
Current profitability levels for the company are sitting at:
- -1349.19 for the present operating margin
- -9.78 for the gross margin
The net margin for Quince Therapeutics Inc stands at -1479.56. The total capital return value is set at -0.4. Equity return is now at value -83.18, with -50.27 for asset returns.
Based on Quince Therapeutics Inc (QNCX), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -106.98.
Currently, EBITDA for the company is -31.26 million with net debt to EBITDA at -0.37. When we switch over and look at the enterprise to sales, we see a ratio of 2078.26. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.53.
Conclusion
In a nutshell, Quince Therapeutics Inc (QNCX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
